Instil Bio, Inc.(TIL)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TIL Instil Bio, Inc.

交易中 02-27 13:02:09 EST

8.83

-0.16

-1.78%

最高9.28	最低8.80	成交量2.06万
今开9.00	昨收8.99	日振幅5.34%
总市值5,988万	流通市值2,921万	总股本678.20万
成交额18.47万	换手率0.62%	流通股本330.81万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TIL","market":"US","secType":"STK","nameCN":"Instil Bio, Inc.","latestPrice":8.83,"timestamp":1772215136049,"preClose":8.99,"halted":0,"volume":20598,"delay":0,"changeRate":-0.017797552836484997,"floatShares":3308074,"shares":6781976,"eps":-11.368316,"marketStatus":"交易中","change":-0.16,"latestTime":"02-27 13:02:09 EST","open":9,"high":9.28,"low":8.8,"amount":184721.154366,"amplitude":0.053393,"askPrice":8.82,"askSize":105,"bidPrice":8.61,"bidSize":192,"shortable":3,"etf":0,"ttmEps":-11.368316,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772226000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1616126400000,"exchange":"NASDAQ","adjPreClose":8.99,"postHourTrading":{"tag":"盘后","latestPrice":8.99,"preClose":8.99,"latestTime":"16:10 EST","volume":26,"amount":233.74,"timestamp":1772140204372,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.901083,"impliedVol":5.6162,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/TIL","defaultTab":"news","newsList":[{"id":"2602354601","title":"宜明昂科与Instil Bio“分手” 超20亿美元BD合作终止","url":"https://stock-news.laohu8.com/highlight/detail?id=2602354601","media":"中国经营报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602354601?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:33","pubTimestamp":1768228408,"startTime":"0","endTime":"0","summary":"日前，港股上市公司宜明昂科（01541.HK）发布公告，终止与纳斯达克上市公司InstilBio（TIL.US）旗下子公司AxionBio的许可与合作协议。这笔于2024年8月达成、潜在总价值超过20亿美元的BD（商务拓展）交易，在启动仅一年半后便宣告终结。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601123616136629.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4505","BK4139","TIL"],"gpt_icon":0},{"id":"2601533862","title":"Instil Bio, Inc.盘中异动 快速上涨8.26%报7.21美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2601533862","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601533862?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:31","pubTimestamp":1767796289,"startTime":"0","endTime":"0","summary":"北京时间2026年01月07日22时31分，Instil Bio, Inc.股票出现异动，股价急速上涨8.26%。Instil Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.48%。Instil Bio, Inc.公司简介：Instil Bio Inc 是一家临床阶段的生物制药公司，专注于开发用于治疗癌症患者的自体肿瘤浸润性淋巴细胞的细胞治疗管道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107223129953c28b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107223129953c28b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","TIL"],"gpt_icon":0},{"id":"2601316386","title":"3500万美元到账后，宜明昂科超20亿美元BD合作终止，创始人田文志：美国临床推进缓慢","url":"https://stock-news.laohu8.com/highlight/detail?id=2601316386","media":"时代财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601316386?lang=zh_cn&edition=full","pubTime":"2026-01-07 19:19","pubTimestamp":1767784795,"startTime":"0","endTime":"0","summary":"宜明昂科为何与美国药企终止协议？此次终止不影响宜明昂科已从Axion收到的3500万美元首付款和里程碑付款。临床试验进展乏力成为此次合作终止的导火索。去年8月是宜明昂科最后一次收到BD交易款项，过往五次总计金额为3500万美元，这也是此次交易终止时不可退还的款项。随着BD款项陆续到账，双方的合作项目也在持续推进。但实际上，在2026年开年不到一周，宜明昂科与Instil Bio双方就终止了合作。据公开资料，其于2025年4月开始担任这一职位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107192006a6fe8396&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260107192006a6fe8396&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","LU2778985437.USD","LU0348735423.USD","09926","LU0417516902.SGD","LU0417516571.SGD","LU0561508036.HKD","IE00B543WZ88.USD","LU0348784397.USD","LU1961090484.USD","LU0348767384.USD","LU0634319403.HKD","LU0348827113.USD","LU0417516738.SGD","LU0348825331.USD","TIL","LU0540923850.HKD","BK1161","01541","LU2476274720.SGD","LU1720050803.USD","LU0348766576.USD","LU2476274308.USD","LU0348783233.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","LU2488822045.USD","LU2399975544.HKD","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"1127954762","title":"Instil Bio评级遭Baird下调至中性，目标价大幅调降至7美元以反映现金价值","url":"https://stock-news.laohu8.com/highlight/detail?id=1127954762","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127954762?lang=zh_cn&edition=full","pubTime":"2026-01-07 13:55","pubTimestamp":1767765315,"startTime":"0","endTime":"0","summary":"投资机构Baird宣布将Instil Bio, Inc.的股票评级从\"跑赢大盘\"下调至\"中性\"，同时将其目标股价从180美元大幅削减至7美元。此次调整主要基于该公司当前的近似现金价值进行重新评估。\n分析师指出，此次评级和目标价的双重下调反映了对Instil Bio业务前景的审慎看法。目标价调整为7美元意味着较先前180美元的目标价出现显著缩水，凸显出市场对该生物技术公司价值评估的根本性变化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TIL","BK4505","BK4139"],"gpt_icon":0},{"id":"1126975015","title":"Instil Bio子公司终止Axn-2510临床开发 解除与ImmuneOnco合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1126975015","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126975015?lang=zh_cn&edition=full","pubTime":"2026-01-06 20:00","pubTimestamp":1767700816,"startTime":"0","endTime":"0","summary":"Instil Bio旗下子公司正式宣布，将全面停止肿瘤治疗药物Axn-2510的临床研发计划。与此同时，该公司已与生物技术企业ImmuneOnco达成一致，双方共同终止此前签署的授权及合作协议。这一决定标志着双方在Axn-2510项目上的合作正式画上句号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TIL","BK4505","BK4139"],"gpt_icon":0},{"id":"2595412750","title":"君赛生物：聚焦实体瘤“免清淋”突破，GC101预计2026年提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2595412750","media":"新浪科技","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595412750?lang=zh_cn&edition=full","pubTime":"2025-12-30 10:41","pubTimestamp":1767062460,"startTime":"0","endTime":"0","summary":"新浪科技讯 12月30日上午消息，日前，聚焦实体瘤创新细胞疗法与创新药开发的上海君赛生物股份有限公司 正式向港交所递交招股书，拟依据港股18A章登陆生物科技板块。　　目前，GC101用于治疗黑色素瘤的临床试验正在开展关键II期临床试验，预计将于2026年提交生物制品许可申请；GC101用于治疗非小细胞肺癌的临床管线目前处于Ib期临床。　　按照计划，GC101预计2026年提交上市申请，若成功获批，将成为国内首个上市的TIL疗法。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/newstock/2025-12-30/doc-inhepszw4394800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["TIL","BK4505","ORR","BK4139"],"gpt_icon":0},{"id":"2592903924","title":"Instil Bio, Inc.盘中异动 早盘股价大涨5.33%报11.85美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592903924","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592903924?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:54","pubTimestamp":1765983267,"startTime":"0","endTime":"0","summary":"北京时间2025年12月17日22时54分，Instil Bio, Inc.股票出现波动，股价大幅上涨5.33%。截至发稿，该股报11.85美元/股，成交量6645股，换手率0.10%，振幅3.27%。Instil Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。Instil Bio, Inc.公司简介：Instil Bio Inc 是一家临床阶段的生物制药公司，专注于开发用于治疗癌症患者的自体肿瘤浸润性淋巴细胞的细胞治疗管道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217225427a6ae82f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217225427a6ae82f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","TIL","BK4139"],"gpt_icon":0},{"id":"2581794293","title":"Instil Bio, Inc.盘中异动 股价大跌5.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581794293","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581794293?lang=zh_cn&edition=full","pubTime":"2025-11-05 03:47","pubTimestamp":1762285629,"startTime":"0","endTime":"0","summary":"北京时间2025年11月05日03时47分，Instil Bio, Inc.股票出现异动，股价大幅下挫5.79%。Instil Bio, Inc.股票所在的生物技术行业中，整体跌幅为0.24%。Instil Bio, Inc.公司简介：Instil Bio Inc 是一家临床阶段的生物制药公司，专注于开发用于治疗癌症患者的自体肿瘤浸润性淋巴细胞的细胞治疗管道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110503470994ef2ffb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025110503470994ef2ffb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TIL","BK4505","BK4139"],"gpt_icon":0},{"id":"2576094140","title":"Instil Bio, Inc.盘中异动 早盘大幅跳水5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576094140","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576094140?lang=zh_cn&edition=full","pubTime":"2025-10-17 22:33","pubTimestamp":1760711609,"startTime":"0","endTime":"0","summary":"北京时间2025年10月17日22时33分，Instil Bio, Inc.股票出现波动，股价快速下跌5.03%。Instil Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.23%。Instil Bio, Inc.公司简介：Instil Bio Inc 是一家临床阶段的生物制药公司，专注于开发用于治疗癌症患者的自体肿瘤浸润性淋巴细胞的细胞治疗管道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017223329a6bf09ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251017223329a6bf09ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","TIL"],"gpt_icon":0},{"id":"2568171362","title":"Instil Bio, Inc.盘中异动 大幅下挫5.47%报19.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568171362","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568171362?lang=zh_cn&edition=full","pubTime":"2025-09-20 01:58","pubTimestamp":1758304704,"startTime":"0","endTime":"0","summary":"北京时间2025年09月20日01时58分，Instil Bio, Inc.股票出现异动，股价急速下跌5.47%。Instil Bio, Inc.股票所在的生物技术行业中，整体跌幅为0.30%。Instil Bio, Inc.公司简介：Instil Bio Inc 是一家临床阶段的生物制药公司，专注于开发用于治疗癌症患者的自体肿瘤浸润性淋巴细胞的细胞治疗管道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250920015825a72aa7c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250920015825a72aa7c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","TIL"],"gpt_icon":0},{"id":"2566695982","title":"Instil Bio, Inc.盘中异动 股价大跌5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2566695982","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566695982?lang=zh_cn&edition=full","pubTime":"2025-09-11 01:37","pubTimestamp":1757525844,"startTime":"0","endTime":"0","summary":"北京时间2025年09月11日01时37分，Instil Bio, Inc.股票出现波动，股价急速下挫5.22%。Instil Bio, Inc.股票所在的生物技术行业中，整体涨幅为1.01%。Instil Bio, Inc.公司简介：Instil Bio Inc 是一家临床阶段的生物制药公司，专注于开发用于治疗癌症患者的自体肿瘤浸润性淋巴细胞的细胞治疗管道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091101372497869596&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091101372497869596&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TIL","BK4505"],"gpt_icon":0},{"id":"2518278421","title":"Instil Bio, Inc.盘中异动 早盘急速下跌6.20%报17.17美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518278421","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518278421?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:49","pubTimestamp":1741614583,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时49分，Instil Bio, Inc.股票出现波动，股价快速下挫6.20%。Instil Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。其相关个股中，Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Mineralys Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为2730.30%、614.68%、94.89%，振幅较大的相关个股有Scisparc Ltd.、Impact Biomedical, Inc.、Trevi Therapeutics, Inc.，振幅分别为40.24%、28.59%、25.35%。Instil Bio, Inc.公司简介：Instil Bio Inc 是一家临床阶段的生物制药公司，专注于开发自体肿瘤浸润淋巴细胞的细胞治疗管道，以治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214943a26a2bd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214943a26a2bd0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","TIL"],"gpt_icon":0},{"id":"2518440860","title":"Instil Bio, Inc.2024财年实现净利润-74.14百万美元，同比增加52.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518440860","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518440860?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449706,"startTime":"0","endTime":"0","summary":"3月9日，Instil Bio, Inc.公布财报，公告显示公司2024财年净利润为-74.14百万美元，同比增加52.47%；其中营业收入为0.00美元，每股基本收益为-11.39美元。从资产负债表来看，Instil Bio, Inc.总负债95.32百万美元，其中短期债务1.68百万美元，资产负债比为0.03，流动比率为0.16。机构评级：截至2025年3月9日，当前有3家机构对Instil Bio, Inc.目标价做出预测，其中目标均价为113.67美元，其中最低目标价为51.00美元，最高目标价为180.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000330a266b4d2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000330a266b4d2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TIL"],"gpt_icon":0},{"id":"2516677748","title":"Instil Bio, Inc.盘中异动 股价大跌6.73%报17.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516677748","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516677748?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:52","pubTimestamp":1741099933,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时52分，Instil Bio, Inc.股票出现异动，股价大幅下挫6.73%。截至发稿，该股报17.05美元/股，成交量2.3636万股，换手率0.36%，振幅7.99%。Instil Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.32%。Instil Bio, Inc.公司简介：Instil Bio Inc 是一家临床阶段的生物制药公司，专注于开发自体肿瘤浸润淋巴细胞的细胞治疗管道，以治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422521396394b2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030422521396394b2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","TIL"],"gpt_icon":0},{"id":"1145020564","title":"Instil Bio公司2024年第四季度GAAP每股收益$(1.82)优于预期$(3.22)，公司拥有现金、现金等价物、受限现金和有价证券共$1.151亿，预计可支撑现有运营计划到2026年之后","url":"https://stock-news.laohu8.com/highlight/detail?id=1145020564","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145020564?lang=zh_cn&edition=full","pubTime":"2025-03-04 20:20","pubTimestamp":1741090856,"startTime":"0","endTime":"0","summary":"Instil Bio报告季度每股亏损$，优于分析师一致预期的$，提高了43.48%。相比于去年同期的每股亏损$，增加了8.54%。以上内容来自Benzinga Earnings专栏，原文如下：Instil Bio  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 43.48 percent. This is a 8.54 percent increase over losses of $ per share from the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TIL","TSS"],"gpt_icon":0},{"id":"2516632523","title":"Instil Bio, Inc.盘中异动 股价大涨8.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516632523","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516632523?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:31","pubTimestamp":1741012302,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时31分，Instil Bio, Inc.股票出现波动，股价大幅拉升8.21%。Instil Bio, Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Entero Therapeutics Inc.、Alto Neuroscience, Inc.、Geovax Labs, Inc.涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为47.20%、24.44%、22.45%，振幅较大的相关个股有Entero Therapeutics Inc.、Cibus, Inc.、Galmed Pharmaceuticals Ltd.，振幅分别为15.16%、9.55%、9.35%。Instil Bio, Inc.公司简介：Instil Bio Inc 是一家临床阶段的生物制药公司，专注于开发自体肿瘤浸润淋巴细胞的细胞治疗管道，以治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223142abe63312&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303223142abe63312&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","TIL"],"gpt_icon":0},{"id":"2516304531","title":"Instil Bio, Inc.盘中异动 急速上涨5.02%报20.29美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516304531","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516304531?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:58","pubTimestamp":1740776308,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时58分，Instil Bio, Inc.股票出现波动，股价快速拉升5.02%。Instil Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.69%。Instil Bio, Inc.公司简介：Instil Bio Inc 是一家临床阶段的生物制药公司，专注于开发自体肿瘤浸润淋巴细胞的细胞治疗管道，以治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010458289896c8a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010458289896c8a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","TIL"],"gpt_icon":0},{"id":"2513216212","title":"Instil Bio, Inc.盘中异动 股价大跌5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513216212","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513216212?lang=zh_cn&edition=full","pubTime":"2025-02-22 02:13","pubTimestamp":1740161597,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日02时13分，Instil Bio, Inc.股票出现异动，股价急速下挫5.33%。Instil Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。其相关个股中，Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Invivyd, Inc.、Osr Holdings, Inc.涨幅较大，Aditxt, Inc.、Nkgen Biotech, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为261.86%、243.77%、135.59%，振幅较大的相关个股有Osr Holdings, Inc.、Invivyd, Inc.、Osr Holdings Inc C/Wts 09/02/2028 ，振幅分别为76.52%、70.25%、57.50%。Instil Bio, Inc.公司简介：Instil Bio Inc 是一家临床阶段的生物制药公司，专注于开发自体肿瘤浸润淋巴细胞的细胞治疗管道，以治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222021317962bad70&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222021317962bad70&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TIL","BK4505","BK4139"],"gpt_icon":0},{"id":"2512388114","title":"Instil Bio, Inc.盘中异动 下午盘股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512388114","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512388114?lang=zh_cn&edition=full","pubTime":"2025-02-20 02:03","pubTimestamp":1739988201,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日02时03分，Instil Bio, Inc.股票出现波动，股价大幅下挫5.00%。Instil Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.52%。Instil Bio, Inc.公司简介：Instil Bio Inc 是一家临床阶段的生物制药公司，专注于开发自体肿瘤浸润淋巴细胞的细胞治疗管道，以治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220020321a24c216f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220020321a24c216f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TIL","BK4505","BK4139"],"gpt_icon":0},{"id":"2512652601","title":"Instil Bio, Inc.盘中异动 股价大涨7.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512652601","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512652601?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:39","pubTimestamp":1739889589,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时39分，Instil Bio, Inc.股票出现异动，股价快速上涨7.82%。Instil Bio, Inc.股票所在的生物技术行业中，整体涨幅为0.40%。其相关个股中，Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Pulmatrix, Inc.涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为298.00%、103.52%、82.47%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Conduit Pharmaceuticals Inc.、Pulmatrix, Inc.，振幅分别为34.04%、26.83%、23.16%。Instil Bio, Inc.公司简介：Instil Bio Inc 是一家临床阶段的生物制药公司，专注于开发自体肿瘤浸润淋巴细胞的细胞治疗管道，以治疗癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021822394996279934&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021822394996279934&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","TIL","BK4505"],"gpt_icon":0}],"profile":{"websiteUrl":"https://instilbio.com/","stockEarnings":[{"period":"1week","weight":-0.0537},{"period":"1month","weight":0.2556},{"period":"3month","weight":-0.2955},{"period":"6month","weight":-0.667},{"period":"1year","weight":-0.5505},{"period":"ytd","weight":-0.1827}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Instil Bio, Inc.总部位于德克萨斯州达拉斯，于2018年8月在特拉华州注册成立。该公司是一家临床阶段生物制药公司，致力于开发创新的自体肿瘤浸润淋巴细胞（TIL）治疗细胞疗法，以治疗癌症患者。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.065377},{"month":2,"riseRate":0.4,"avgChangeRate":0.013099},{"month":3,"riseRate":0.25,"avgChangeRate":-0.094518},{"month":4,"riseRate":0.2,"avgChangeRate":-0.158547},{"month":5,"riseRate":0.2,"avgChangeRate":0.143926},{"month":6,"riseRate":0.2,"avgChangeRate":-0.098253},{"month":7,"riseRate":0.6,"avgChangeRate":0.06531},{"month":8,"riseRate":0.6,"avgChangeRate":0.054198},{"month":9,"riseRate":0.2,"avgChangeRate":0.663025},{"month":10,"riseRate":0.2,"avgChangeRate":-0.170435},{"month":11,"riseRate":0.2,"avgChangeRate":-0.206869},{"month":12,"riseRate":0.2,"avgChangeRate":-0.210371}],"exchange":"NASDAQ","name":"Instil Bio, Inc.","nameEN":"Instil Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Instil Bio, Inc.(TIL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Instil Bio, Inc.(TIL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Instil Bio, Inc.,TIL,Instil Bio, Inc.股票,Instil Bio, Inc.股票老虎,Instil Bio, Inc.股票老虎国际,Instil Bio, Inc.行情,Instil Bio, Inc.股票行情,Instil Bio, Inc.股价,Instil Bio, Inc.股市,Instil Bio, Inc.股票价格,Instil Bio, Inc.股票交易,Instil Bio, Inc.股票购买,Instil Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Instil Bio, Inc.(TIL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Instil Bio, Inc.(TIL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}